Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transurethral prostatectomy: mortality and morbidity

W Horninger1, H Unterlechner, H Strasser

  • 1Department of Urology, University of Innsbruck, Austria.

The Prostate
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trend analysis and regional tumor incidence in Germany for testicular cancer between 2003 and 2014.

Andrology·2019
Same author

[Unexpected differential diagnosis of urachal cancer].

Der Urologe. Ausg. A·2018
Same author

[Urolithiasis 2016 : Reliable, effective and low radiation exposure].

Der Urologe. Ausg. A·2016
Same author

[Patient blood management: Current state of the literature].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2015
Same author

Rapid effect of an elicitor on uptake and intracellular distribution of phosphate in cultured parsley cells.

Plant cell reports·2013
Same author

[Cystectomy in the elderly patient].

Der Urologe. Ausg. A·2013
Same journal

Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer.

The Prostate·2026
Same journal

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia.

The Prostate·2026
Same journal

Temporal Trends of Metastatic Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era in the United States.

The Prostate·2026
Same journal

Holmium Laser Enucleation of the Prostate (HoLEP) With Proactive Preservation of One Lateral Lobe: A Technique for Benign Prostatic Hyperplasia to Preserve Sexual Function.

The Prostate·2026
Same journal

Clinical Variable-Based Machine Learning for Predicting Early mCRPC Using Exclusively Clinical Variables: Development and Multicenter External Validation.

The Prostate·2026
Same journal

Association Between Intraoperative Prostate Bed Blood Flow and Postoperative Lower Urinary Tract Symptoms After Robot-Assisted Radical Prostatectomy.

The Prostate·2026
See all related articles

Transurethral resection of the prostate (TURP) is a safe procedure with a 0% mortality rate. This study found lower repeat TURP rates compared to previous large-scale research.

Area of Science:

  • Urology
  • Surgical Outcomes
  • Patient Safety

Background:

  • Two major studies in 1989 highlighted transurethral resection of the prostate (TURP) mortality and morbidity.
  • Concerns arose regarding the safety and outcomes of TURP procedures.

Purpose of the Study:

  • To retrospectively analyze the safety and efficacy of TURP.
  • To compare TURP outcomes with previously published multicenter studies.

Main Methods:

  • Retrospective analysis of 1,211 consecutive patients undergoing TURP between January 1988 and July 1991.
  • Data collection on intraoperative, early postoperative, and late postoperative complications.
  • Follow-up of 775 patients for at least one year post-surgery.
  • Comparison of complication and re-operation rates with Mebust et al. and Roos et al. studies.

Related Experiment Videos

Main Results:

  • Zero mortality rate (0.00%) for TURP.
  • Intraoperative complication rate: 8.9%.
  • Early postoperative complication rate: 15.8%.
  • Late complication rate: 11.2% in patients followed for at least one year.
  • Repeat TURP rates: 0.9% within 1 year and 2.5% within 3 years.
  • Significantly lower mortality and repeat TURP rates compared to Mebust et al. and Roos et al.

Conclusions:

  • TURP demonstrates a very low mortality rate and manageable complication profile.
  • The study's TURP outcomes, particularly regarding mortality and repeat procedures, are favorable compared to landmark studies.
  • TURP remains a safe and effective treatment option for benign prostatic hyperplasia.